Initial Pharmacologic Management of New Onset Diabetes Mellitus

Standard Initial Approach

The American Diabetes Association recommends metformin as the preferred initial pharmacologic agent for new onset type 2 diabetes mellitus, unless contraindicated or not tolerated, due to its beneficial effects on A1C, weight, and cardiovascular mortality compared to other first-line agents, supported by Level A evidence 1, 2, 3
Metformin should be started at 500 mg orally twice daily with meals and titrated gradually to the maximum effective dose of 2000 mg daily to minimize gastrointestinal side effects, as recommended by the American Diabetes Association 4

Metformin is weight neutral or promotes weight loss rather than weight gain, and has a low hypoglycemia risk, allowing less frequent glucose monitoring, according to the American Diabetes Association 1, 5
Metformin is inexpensive and widely available, and is safe in renal impairment down to eGFR ≥30 mL/min/1.73 m², as stated by the American College of Physicians 3, 1, 2

The American Diabetes Association recommends initiating basal insulin (with or without metformin) immediately if the patient presents with A1C ≥10%, random blood glucose ≥300 mg/dL, symptomatic hyperglycemia, or any degree of ketosis or ketoacidosis 1, 2, 3, 5
For patients with A1C ≥8.5% who are symptomatic, the American Diabetes Association suggests starting basal insulin at 0.5 units/kg/day while simultaneously initiating metformin, and tapering insulin by 10-30% every few days while continuing metformin once glycemic control improves 4

The American Diabetes Association recommends assessing A1C every 3 months and intensifying treatment if glycemic goals are not met, and not delaying treatment intensification beyond 3 months of inadequate response 1, 7, 4, 6
The American College of Physicians suggests checking vitamin B12 levels periodically, especially in patients with anemia or peripheral neuropathy, as metformin is associated with biochemical B12 deficiency 1, 2, 3, 4

The American Diabetes Association advises stopping metformin during acute illness with nausea, vomiting, or dehydration, and avoiding metformin if eGFR <30 mL/min/1.73 m² 1, 3
Gastrointestinal side effects are common but often transient; starting at low doses and gradual titration minimizes these effects, as recommended by the American Gastroenterological Association 5, 7, 3

The American Diabetes Association recommends aiming for A1C <7% for most patients treated with oral agents, with more stringent targets (<6.5%) for patients with short disease duration and lesser β-cell dysfunction, and less stringent targets (≥7.5%) for those with history of severe hypoglycemia, limited life expectancy, or advanced complications 4, 6